Alaunos Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Alaunos Therapeutics sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Alaunos Therapeutics: 22 sponsored US clinical trials, none currently recruiting.
Alaunos Therapeutics sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 1 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 2 trials.
Top-decile sponsor footprint
Alaunos Therapeutics ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05194735
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
NCT05124743
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
NCT04006119
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
NCT03679754
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
NCT03636477
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
NCT03330197
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
NCT02423902
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
NCT02026271
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
NCT01703754
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
NCT01397708
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
NCT01168791
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
NCT01139346
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
NCT00815607
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
NCT00608803
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
NCT00591890
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
NCT00421213
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
NCT00421135
Study of ZIO-201 in Advanced Sarcoma
NCT00439686
Study of ZIO-101 in Multiple Myeloma
NCT00303199
A Phase I Trial of ZIO-101 in Solid Tumors
NCT00591396
A Phase I Trial of ZIO-101 in Hematologic Cancers
NCT00592046
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
How the Alaunos Therapeutics early-phase archive is shaped
22 indexed studies, none listed as recruiting (0% open); 16 completed (73%).
Phase mix: 1 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (2 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Alaunos Therapeutics: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Alaunos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
- Griffin Hospital · 22 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Alaunos Therapeutics page
22 registered trials is a research-attention snapshot, not an endorsement of Alaunos Therapeutics or any single study.
- None of Alaunos Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Cancer is the condition Alaunos Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alaunos Therapeutics pipeline card: 22 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.